Article

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

2015-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a33fc849-831c-55dc-a28f-287559d86c41
DOI: 10.1186/2051-1426-3-s2-p134
PMCID: PMC4646106

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patientsDOI 10.1186/2051-1426-3-s2-p134Read

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.Semantic proximity Read

BRAF in early stage melanoma: rationale for testing and treatment?Semantic proximity Read

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.Semantic proximity Read

The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.Semantic proximity Read

Resistance to BRAF inhibition in melanomas.Semantic proximity Read

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models.Semantic proximity Read

Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patientsSemantic proximity Read

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Semantic proximity Read